Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Myomo Expands MyoPro® Centers of Excellence Program

Posted on: 29 Nov 17

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced the addition of six new orthotics and prosthetics (O&P) locations to its Center of Excellence (CoE) program, which recognizes top O&P practices that support the MyoPro line of powered orthoses. MyoPro is currently the only lightweight wearable device that can help restore function in the paralyzed or weakened arms and hands of individuals who have suffered a stroke, brachial plexus injury (BPI) or other neuromuscular disability. With the orthosis, a paralyzed individual can perform activities of daily living including feeding themselves, carrying objects and doing household tasks, and many are able to return to work.

The additions to the CoE program build upon the Company’s footprint as it targets a presence in all the top metropolitan areas in the U.S. These include three new organizations, as well as three new locations of Geauga Rehabilitation Engineering (GRE), an original Myomo CoE. The new locations are:

  • Loma Linda University Medical Center, Loma Linda, CA
  • Orthocraft, Brooklyn, NY
  • Cunningham Prosthetic Care, Portland area, ME
  • GRE locations in Columbus, OH, Cincinnati, OH and Detroit, MI

“We launched our Center of Excellence program in order to better support O&P practices who have shown a commitment to patient care by providing the MyoPro device,” said Paul R. Gudonis, Chairman and CEO of Myomo. “Adding these new practices to our CoE roster just four months after launching the program enables us to serve an increasing number of patients across the country who may be able to benefit from the MyoPro orthosis.”

Myomo CoEs participate in joint marketing efforts and receive training and patient support from Myomo. They also partner with physicians and therapists at leading U.S. rehabilitation hospitals, who recommend and prescribe MyoPro as well as train new MyoPro users.

“Our strong relationship with Myomo has translated into exceptional patient outcomes, which have always been our priority,” said Vince Baroni, Clinical Director for GRE. “MyoPro is an innovative device that has benefited dozens of GRE patients, many of whom had lost hope of ever using their paralyzed arm again. The new Myomo CoEs in our organization will now be able to better support such individuals.”

About Myomo

Myomo, Inc. is a commercial stage medical robotics company that develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to help restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient’s own EMG signals through non-invasive sensors on the arm, can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S. For more information, please visit

Forward Looking Statements

This press release contains forward-looking statements regarding the Company's future business expectations, including the therapeutic benefit of the Company’s products, its expectations related to the CoE program and market penetration and expansion, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and may differ materially from actual results due to a variety of factors. Our actual results could differ materially from those anticipated in these forward looking statements for many reasons, including, without limitation, risks related to regulatory approval and market acceptance of our products, and the other risk factors contained in our filings made with the Securities and Exchange Commission. More information about factors that potentially could affect Myomo's financial results is included in Myomo's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

View source version on

Business Wire

Last updated on: 29/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.